Other substances

Interferon alfa-2b

A recombinant signalling protein factor.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
14
 AI-suggested references
1
 Clinical trials

General information

Interferon alfa-2b is a recombinant type I interferon with antiviral and antineoplastic properties (DrugBank).

Interferon alfa-2b on Wikipedia

Synonyms

Interferon alpha-2b; IFN-α2b

 

Structure image - Interferon alfa-2b

CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI


QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVR


KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE

Supporting references

Link Tested on Impact factor Notes Publication date
Therapeutic effectiveness of interferon-alpha2b against COVID-19: the Cuban experience
Preprint 		Patients

used in combination with antivirals lopinavir/ritonavir and chloroquine

 Jun/09/2020
Interferon-α2b Treatment for COVID-19 Is Associated with Improvements in Lung Abnormalities
Protein factor Cohort study 		Patients 3.82

Significant average reduction in upper respiratory tract viral loads and markers of inflammation by day 7. Lower increase during the course of the disease and final pulmonary CT scores were observed in patients who were administered interferon, as well. Sample size: 7 (nebulized IFN-α2b) + 46 (nebulized IFN-α2b and arbidol) + 24 control (arbidol only). Dosage: 5m IU.

 Dec/30/2020

AI-suggested references

Link Publication date
Interferon-alpha2b induced anemia in severe coronavirus disease 2019 patients: a single centered, retrospective study.
Oct/26/2021
Therapeutic Effectiveness of Interferon Alpha 2b Treatment for COVID-19 Patient Recovery.
May/12/2022
Long-term application of hydroxychloroquine could not prevent the infection of COVID-19.
Mar/02/2021
[In vitro activity of human recombinant alpha-2b interferon against SARS-CoV-2 virus].
May/15/2021
Interferon-alpha2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study
Apr/24/2020
Efficacy and safety of pegylated interferon-alpha2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study.
Aug/21/2021
Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.
Jul/18/2020
Comparative therapeutic efficacy of interferon alpha-2b and combination lopinavir/ritonavir plus interferon alpha-2b against SARS-CoV-2.
Aug/30/2021
Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19
May/19/2021
Interferon-alpha2b Treatment for COVID-19
Nov/15/2021
Efficacy and safety of pegylated interferon alpha-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study.
Mar/10/2021
Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19
Jun/17/2020
Arbidol/IFN-alpha2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study
May/20/2020
Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study.
Oct/02/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04379518 Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients Recruiting Phase 1|Phase 2 Nov/17/2020 Nov/17/2023
  • Alternative id - I 659920|NCI-2020-02317|P30CA016056
  • Interventions - Other: Best Practice|Biological: Recombinant Interferon Alfa-2b|Drug: Rintatolimod
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Roswell Park Cancer Institute, Buffalo, New York, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 64
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Incidence of adverse events (AEs)|Kinetics of viral load|Clinical efficacy|Kinetics of changes of the immune subsets and circulating inflammatory mediators in peripheral blood
Export (.csv)